Compare Abeona Therapeutics Inc (ABEO) vs S&P Global Inc (SPGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs S&P Global Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while S&P Global Inc trades at $433.89 (market cap $131.26B). The key difference: S&P Global Inc is far larger — about 351.6× Abeona Therapeutics Inc's market cap, and S&P Global Inc pays a 0.87% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SPGI | |
|---|---|---|
Market Cap | $373.32M | $131.26B |
Sector | Health | Financials |
52-Week High | $7.23 | $534.79 |
52-Week Low | $4.17 | $370.42 |
Enterprise Value | $228.22M | $143.23B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
S&P Global (SPGI) trades at $443.46, up 0.81% with strong bullish momentum. The stock shows robust fundamentals with 29.15% net margin and consistent earnings beats in three of the last four quarters. Recent completion of Mobility Global spinoff and AI-driven market intelligence initiatives position the company for growth. Technical indicators show bullish moving averages while RSI suggests potential overbought conditions near-term.
Outlook remains positive with 85.7% analyst buy ratings and $533.50 consensus target implying 20% upside. Key risks include interest rate sensitivity in credit rating segment and execution of AI transformation. The company's subscription-based revenue model and market data dominance provide stable cash flow foundation for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
